Objective: The purpose of this study was to identify the clinicopathological characteristics and prognostic value of p53 overexpression in breast cancer patients treated with a modified radical mastectomy. Methods: The medical records of 197 patients who had undergone modified radical mastectomy between January 1991 and December 2008 were reviewed retrospectively. Breast cancer subtype and p53 overexpression were investigated using immunohistochemistry and/ or fluorescent in situ hybridization analysis of surgical specimens. Results: The median follow-up after the modified radical mastectomy was 56.1 months (range, 14.7 -232.7). The median age was 47 years (range, 31 -72). p53 overexpression was noted in 73 patients (37.1%). Breast cancer-specific death rate (P ¼ 0.011), cancer progression (P ¼ 0.024), distant metastasis (P ¼ 0.015), hormone receptor negativity (P , 0.001) and human epidermal growth factor receptor 2 positivity (P ¼ 0.017) were detected more frequently in patients with p53 overexpression. The overall survival rates were significantly lower in the p53-overexpression group than in the non-p53-overexpression group (P ¼ 0.021, log-rank test). In the multivariate analysis, p53 overexpression showed the strongest prognostic significance in patients aged ,50 years (P ¼ 0.039) and with the triple-negative subtype (P ¼ 0.023). Conclusions: p53 overexpression correlated with breast cancer-specific death rates and adverse prognostic factors in patients treated with modified radical mastectomy. p53 overexpression might be a more reliable prognosticator in patients aged ,50 years and with the triple-negative subtype. More effective systemic treatments might be warranted for these patients exhibiting p53 overexpression. Further validation is required to make more definite conclusions.
INTRODUCTION
Over the past few decades, a number of potential prognostic markers for breast cancer have been extensively investigated (1 -5) . With the development of innovative techniques for gene expression profiling, novel molecular markers and p53 overexpression has been observed in 20 -50% of primary breast tumors (11) . Several studies have found that mutation or overexpression of p53 is significantly associated with young or pre-menopausal patients (12) (13) (14) .
Because the mutated p53 gene might induce accumulation in the nucleus of tumor cells, immunohistochemical (IHC) staining is used to detect p53 mutations. Although the current evidence for p53 overexpression is insufficient for p53 to be recommended as an independent prognostic marker (15) , recent reports suggest that p53 overexpression might serve as a specific prognostic marker in a specific subgroup of patients (16 -19) . However, it still remains unclear whether p53 overexpression could be added as a prognostic factor within a specific subgroup of patients.
The aim of this study was to identify the clinicopathological characteristics associated with p53 overexpression and the potential prognostic value of p53 overexpression in patients treated with modified radical mastectomy (MRM). Subgroup analyses were also performed to investigate whether the prognostic role of p53 overexpression differs among patient subgroups.
PATIENTS AND METHODS

PATIENT POPULATION
We reviewed the medical records of breast cancer patients who underwent MRM between January 1991 and December 2008 at St Vincent's Hospital. We obtained institutional review board approval to conduct this study. Patients with the following characteristics were excluded from this study: males; Stage IV disease initially; synchronous bilateral breast cancer; diagnosis of cancer other than non-melanomatous skin cancer previously or during the treatment; tumor histology other than invasive ductal or lobular carcinoma; not receiving a standard MRM; and treatment with chemotherapy or hormonal therapy before surgery. We attempted to contact patients or primary physicians in cases of follow-up loss at St Vincent's Hospital to obtain the clinical information. One hundred ninety-seven patients were eligible for inclusion. Because some medical records were inadequate before 2000, only 15 patients were included in this study for the time frame of January 1991 to December 1999.
TREATMENTS
All of the eligible patients underwent MRM with surgical lymph node dissection. Sentinel lymph node biopsies were not performed. Level I and II lymph node dissections were routinely performed. In patients with grossly involved level II nodes, level III dissections were selectively performed. Post-mastectomy radiation therapy was performed in patients who were at high risk for recurrence at the discretion of the radiation and/or surgical oncologist. Radiation was generated using a linear accelerator-based radiation unit with 6 -15 MV photon beams and 6 -18 MV electron beams. The chest wall and supraclavicular lymph nodes (SCLs) were treated with photon beams, and the tumor bed boost was given using electron beams at the appropriate energy to provide coverage of the target volumes. An additional tumor bed boost was administered when the margin status was shown to be close (,2 mm) or positive in the pathologic report with doses between 9 and 19.8 Gy. Chemotherapy and hormonal therapy were performed at the discretion of the surgical and/or medical oncologist.
IMMUNOHISTOCHEMISTRY
IHC was performed on formalin-fixed, paraffin-embedded breast cancer tissue specimens. The following biomarkers were stained: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and p53. IHC was performed with anti-ER (1:100, clone SP1; Dako, Glostrup, Denmark), anti-PR (1:200, clone PgR 636; Dako) and anti-HER2 (1:100, clone SP3; Thermo, Fremont, CA, USA). The ER and PR analyses were based on an IHC assay, in which a report of 10% of the cells with nuclear staining for either ER or PR was defined as positive. IHC for p53 was performed with antibodies to p53 (1:100, clone SP5; Neomarkers, Fremont, CA, USA). p53 status was defined as positive if the percentage of cells with antibody nuclear staining was 10%. We routinely use IHC to define HER2 status. HER2 immunoreactivity was assessed using the following scoring system: 0, no immunoreactivity or immunoreactivity in ,10% of tumor cells; 1þ, faint weak and incomplete staining of .10% of tumor cells; 2þ, weak-to-moderate complete membrane immunoreactivity in .10% of tumor cells; and 3þ, moderate-to-strong complete membrane immunoreactivity in .10% of tumor cells. HER2 status was regarded as negative if the score was 0 or 1þ, and equivocal if the score was 2þ. HER2 status was regarded as positive if HER2 gene amplification was detected using fluorescence in situ hybridization (FISH) or if the IHC score was 3þ. FISH was performed selectively when the score was 2þ. The PathVysion HER2/neu probe kit (Vysis Inc., Downers Grove, IL, USA) was used for FISH analysis.
Hormone receptor (HR) status was regarded as negative when ER and PR were both negative and positive when ER and/or PR were positive. Breast cancer molecular subtype was classified into four groups based on the IHC and FISH profile of ER/PR and HER2 expression as follows: luminal type A, at least one of the HRs is positive and HER2 is negative; luminal type B, at least one of the HRs is positive and HER2 is positive; HER2þ type, both of the HRs are negative and HER2 is positive; and triple-negative (TN) type, both of the HRs are negative and HER2 is negative.
STUDY ENDPOINTS
The primary endpoint was overall survival (OS). OS was defined as the time from the surgery to the date of death by breast cancer cause-specific factors or the patient's last visit.
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The secondary endpoints were locoregional recurrence (LRR) and distant metastasis (DM). LRR was defined as the time to the first event of isolated tumor recurrence at the mastectomy site or regional lymph node area. DM was defined as the time to the first event of metastasis to distant sites. DM was classified as non-skeletal DM (NSDM) and skeletal DM (SDM) according to the sites of metastasis. Synchronous recurrence in locoregional and distant sites was regarded as DM, and synchronous metastasis in SDM and NSDM was regarded as NSDM. When DM developed within the first month of LRR, the event was defined as DM.
FOLLOW-UP
Patients were reevaluated 6 -8 weeks after the completion of radiation therapy and then every 2 -3 months during the first year. Thereafter, follow-up was performed every 6 -12 months. Breast imaging was performed routinely, and Tc-99m whole-body bone scans or positron emission tomography/computed tomography was performed selectively when clinically indicated. Diagnosis of LRR and DM was based largely on the radiological and clinical findings, and pathological or cytological confirmation was used selectively to discriminate suspicious lesions.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS (version 12.0; SPSS Inc., Chicago, IL, USA). The differences between variables were compared using the x 2 test for categorical variables, and ANOVA and t-test for quantitative or continuous variables. Clinicopathological correlations between variables were evaluated by logistic regression analysis. For survival analysis, the Kaplan -Meier curves were generated and assessed by a log-rank test. For multivariate analysis, the Cox proportional hazards regression model was used to identify independent prognostic factors. Inclusion of covariables in the multivariate analysis was based on the covariables that were significant in the univariate analysis. All of the statistical tests were two-sided, and a P value of ,0.05 was considered significant.
RESULTS
PATIENT, TUMOR AND TREATMENT CHARACTERISTICS BASED ON P53 OVEREXPRESSION
The patient, tumor and treatment characteristics based on p53 overexpression are presented in Table 1 . All of the tumor characteristics were based on information in the pathology reports. The median age was 47 years (range, 31 -72). p53 overexpression was detected in 73 patients (37.1%). The proportion of T1 and T2 stages was higher in the non-p53-overexpression arm (P ¼ 0.026). However, the mean maximal tumor diameter did not differ between the two arms (P ¼ 0.443); the mean maximal tumor diameter was 3.72 cm in the p53-overexpression arm and 3.46 cm in the non-p53-overexpression arm. The N stage, tumor -nodemetastasis (TNM) stage, the mean number of dissected lymph nodes and the mean number of involved lymph nodes also did not differ significantly between the two arms (P ¼ 0.509, 0.672, 0.320 and 0.094, respectively). The proportion of patients positive for HR, ER, PR and HER2 differed significantly between the two arms (P , 0.001, ,0.001, 0.001 and 0.017, respectively).
Forty patients (64.5%) received irradiation of the chest wall with separate irradiation of the SCLs and internal mammary nodes (IMNs). Twenty patients (32.3%) received irradiation of the chest wall and separate irradiation of the SCLs. The remaining two patients (3.2%) received irradiation only to the chest wall. The median total dose and dose per fraction to the chest wall were 50.4 Gy and 180 cGy, respectively. The median total doses to the SCL and IMN fields were 50.4 and 50.4 Gy, respectively. Adjuvant systemic chemotherapy was delivered in 172 patients (87.3%) using cyclophosphamide, methotrexate and fluorouracil; anthracycline; or taxane-based regimens. One hundred seven patients (62.2%) were treated with a taxane and anthracycline (with or without fluoropyrimidine) combination chemotherapeutic regimen. The distribution of combination regimens was as follows: doxorubicin and cyclophosphamide (AC) plus taxol (T); docetaxel, doxorubicin and cyclophosphamide (DAC); epirubicin, cyclophosphamide and fluorouracil (ECF); cyclophosphamide, doxorubicin and fluorouracil (CAF); and docetaxel, epirubicin and cyclophosphamide (TEC). The most commonly used combinations were AC þ T and DAC. The median number of chemotherapy cycles was 6 for the DAC, ECF, CAF and TEC combinations, and 4 þ 4 for the AC þ T combination. Adjuvant trastuzumab was not administered. One hundred fifty-six patients (79.2%) received systemic hormonal therapy. The most common hormonal therapy agents were tamoxifen and toremifene in pre-menopausal women, and letrozole and anastrozole in post-menopausal women. The use of chemotherapy and radiation therapy did not differ significantly between the two arms (P ¼ 0.612 and 0.745, respectively). However, hormonal therapy was more frequently administered to the non-p53-overexpression arm (P , 0.001), which might reflect the different distribution of HR status in the two arms.
HER2þ and TN breast cancer molecular subtypes were detected more frequently in the p53-overexpression arm, and the luminal type was detected more frequently in the non-p53-overexpression arm (P , 0.001). Twenty-six of the 42 patients with the TN subtype (61.9%) exhibited p53 overexpression. Conversely, 35 of the 139 patients with the luminal subtype (25.18%) exhibited p53 overexpression. Among the entire population of 73 patients with p53 overexpression, 16.4% were HER2þ and 35.6% had the TN subtype. In contrast, among the 124 patients in the non-p53-overexpression group, 3.2% were HER2þ and 12.9% had the TN subtype.
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p53 overexpression and breast cancer Table 2 . The patterns of failure differed significantly between the two arms. Although the incidence of LRR was similar between the two arms (P ¼ 0.914), the incidence rates of overall DM, overall cancer recurrence and breast cancer-specific death were significantly higher in the p53-overexpression arm (P ¼ 0.015, 0.024 and 0.011, respectively). The NSDM rate was higher in the p53-overexpression arm with a marginal significance (P ¼ 0.057). The OS rate differed between the p53-and non-p53-overexpression arms (P ¼ 0.021) on the log-rank test. The actuarial 5-and 10-year OS rates were 93.1 and 73.6% in the non-p53-overexpression arm and 80.7 and 61.4% in the p53-overexpression arm. The LRR-free survival (LRRFS) rate did not differ significantly between the two arms on the log-rank test (P ¼ 0.733). However, the DM-free survival (DMFS) rate showed a trend toward significance on the log-rank test (P ¼ 0.069). The KaplanMeier curves of OS, LRRFS and DMFS are shown in Fig. 1a -c , respectively.
PROGNOSTIC FACTOR ANALYSIS OF OS, LRRFS AND DMFS
We performed univariate and multivariate analyses of LRRFS, DMFS and OS using the Cox proportional hazards regression model. In the univariate analysis of OS, N stage (P , 0.001), lymphovascular invasion (P ¼ 0.031), breast cancer molecular subtype (P ¼ 0.031), p53 overexpression (P ¼ 0.026) and the use of hormonal therapy (P ¼ 0.016) were significant factors affecting OS. In the multivariate analysis, only N stage (P ¼ 0.024) was an independent prognostic factor affecting OS. In the univariate and multivariate analyses of LRRFS, none of the factors was significantly associated with LRRFS. In the univariate analysis of DMFS, N stage (P , 0.001), extracapsular extension (ECE) or axillary level 3 lymph node involvement (P ¼ 0.001), HER2 positivity (P ¼ 0.011) and ER positivity (P ¼ 0.017) were significant factors affecting DMFS. In the multivariate analysis, N stage (P , 0.001), ECE or axillary level 3 lymph node involvement (P ¼ 0.009) and ER positivity (P ¼ 0.030) were the independent prognostic factors affecting DMFS. p53 overexpression was a marginally significant factor in the 858 p53 overexpression and breast cancer Table 3 .
SUBGROUP AND PROGNOSTIC FACTOR ANALYSES BASED ON AGE AND BREAST CANCER MOLECULAR SUBTYPE
Subgroup analysis based on age and breast cancer molecular subtype was performed to further define the prognostic role of p53 overexpression in these subgroups. An age of 50 years was an ideal cut-point for showing distinctive survival rates between the two groups. In the subgroup aged ,50 years, the OS rate differed significantly between the p53-and non-p53-overexpression arms on the log-rank test (P ¼ 0.008). In contrast, in the subgroup aged 50 years, the OS rate did not differ significantly between the two arms (P ¼ 0.811). The Kaplan-Meier OS curves in the groups aged ,50 and 50 years are shown in Fig. 2a and b, respectively. In the subgroup of TN subtype patients, the OS rate differed significantly between the two arms on the log-rank test (P ¼ 0.047). However, in the subgroup of non-TN subtype patients, the OS rate did not differ between the two arms (P ¼ 0.510). The Kaplan -Meier OS curves for TN and non-TN subtypes are shown in Fig. 3a and b, respectively.
In the univariate and multivariate analyses in these subgroups, p53 overexpression was an independent prognostic factor affecting OS in the subgroups aged ,50 years (P ¼ 0.039) and with the TN subtype (P ¼ 0.023), but not in the subgroups aged 50 years and with the non-TN subtype. The results of univariate and multivariate analyses according to the age and breast cancer molecular subtype are shown in Tables 4 and 5 , respectively.
DISCUSSION
In the current study, we focused on identifying the clinical significance of IHC p53 overexpression in patients treated with MRM grouped according to the age and breast cancer molecular subtype. In the comparison between the p53-and non-p53-overexpression arms, HR negativity and HER2 positivity were more frequently detected in the p53-overexp ression arm. The luminal subtype was more frequently detected in the non-p53-overexpression arm, and the TN and HER2þ subtypes were more frequently detected in the p53-overexpression arm. The use of chemotherapy and radiotherapy was evenly distributed between the two arms. However, because of the high proportion of positive HR patients in the non-p53-overexpression arm, hormonal therapy was more frequently administered to this group. The patterns of failure also differed markedly between the two arms. The overall rates of DM, NSDM, overall recurrence and breast cancer-specific death were significantly higher in the p53-overexpression arm. The results of survival analysis suggested that DM, especially NSDM, was the main cause of decreased OS and worse overall prognosis in the patients in the p53-overexpression arm.
The p53 gene is a tumor-suppressor gene that is located on the short arm of chromosome 17 (17p13.1). Because a mutated p53 gene produces proteins that are not degraded as quickly as the wild-type protein, p53 proteins accumulate and can be detected by IHC. Overexpression of p53 proteins occur more often in patients with hereditary breast cancer syndromes (familial breast and ovarian cancer, and Li -Fraumeni syndromes) than in patients with sporadic breast cancer (11) . A 1999 meta-analysis (20) reported that the presence of p53 mutations confers an independent relative risk of 1.7 (95% confidence interval, 1.2 -2.4) for disease-free and OS. Although methods for identifying more accurate genetic changes in p53 have been developed, these procedures are expensive and inconvenient for daily practice, and not widely available for routine clinical examinations. Instead, a more convenient and practical assay, such as IHC, is more widely used. There are some discrepancies between the results from the mutational analysis obtained from p53 gene sequencing and IHC determination of p53 Jpn J Clin Oncol 2011;41 (7) 861 (21) . Concerns about the IHC detection of p53 overexpression focus on (i) the ability of this method to detect mutated p53 and stabilized wild-type p53; (ii) the possibility of missing the detection of p53 deletions; (iii) the observation that inherited single nucleotide polymorphisms in the MDM2 gene may modify the association between p53 status and breast cancer survival (10, 22, 23) ; and (iv) the confounding effects of different adjuvant treatment schemes. However, p53 mutations, such as splicing and nonsense mutations, are rarely observed (24) , and the costeffectiveness of p53-mutational analysis has not yet been determined. Although the extent and modality of surgical resection might affect the outcomes, several previous reports included the patients treated with either MRM or lumpectomy (20, 25, 26) . The surgical scheme might affect the prognosis and shift the role of known prognostic factors. Because of this, we performed this study in patients treated with a homogeneous surgical scheme, MRM.
The p53 overexpression in breast cancer is associated with poor overall response to endocrine therapy and chemotherapy, and decreased OS rates (19,27 -29) . In the analysis of subgroups classified by age and breast cancer molecular subtype, p53 overexpression was a stronger prognosticator in patients aged ,50 years and with the TN subtype. Similar findings were observed in previous publications. Kim et al. (19) reported that p53 overexpression was significantly associated with tamoxifen resistance in pre-menopausal women. Another study by Talley et al. (17) showed that nuclear accumulation of p53 was prognostically significant only in pre-menopausal women. In the report by Chae et al. (18) , p53 expression was a specific prognostic marker for OS and relapse-free survival in TN-subtype patients but not in non-TN-subtype patients. The common association of p53 overexpression with HR-negative and HER2þ subtypes and the predominant failures in distant sites suggest that more efficacious systemic biological agents are needed to overcome the poor prognosis especially in patients aged ,50 years and with the TN subtype because effective hormonal therapy and chemotherapy are not currently available for patients with these breast cancer subtypes. Recently developed effective strategies that target mutant p53 protein and p53 reactivation have been reported (30, 31) , and these findings may help in the development of strategies to overcoming drug resistance in these patients.
Our current study has some limitations. The conflicting results between various studies might reflect differences in the assays used to detect p53 status, and more accurate techniques are required for more precise outcomes. In the present study, we used a 10% cutoff value for p53 overexpression based on the recommended level in most reports (17 -19,32) . We found no significant differences between the p53-and non-p53-overexpression arms for some adverse tumor characteristics such as lymphovascular invasion, perineural invasion, high histological grade, and multicentricity. In the subgroup analysis of non-TN subtype patients, we found no prognostic role of p53 overexpression, despite a number of censored cases within the 10 years of our study. Further validation with larger populations and long-term follow-up are needed to draw more definitive conclusions. The main strength of this study is the homogeneous surgical modality performed in a single ethnic (Asian) background. We observed a distinctive prognostic role of p53 overexpression among different groups classified by age and breast cancer molecular subtype. However, further studies are needed to determine whether the same results would be found among other ethnic groups or groups under other treatment schemes. Further validation is needed to determine whether IHC p53 status is a cost-effective and reliable indicator that could substitute for genomic profiling in patients aged ,50 years and with the TN subtype.
CONCLUSIONS
The present study demonstrated that p53 overexpression was significantly associated with adverse prognostic factors and poor outcomes in patients treated with MRM. The main mechanism responsible for the decreased OS seemed to relate to NSDM. Our data suggest that, to improved outcomes, a more efficacious systemic treatment is needed for patients exhibiting p53 overexpression, especially those who are younger than 50 years and who have the TN subtype.
Further trials are needed to confirm the role of p53 as a specific prognosticator in breast cancer patients. 
